Drug, bio-affecting and body treating compositions inventions

20080107595 - Anti-ccr5 antibody: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit... Agent: Cooper & Dunham, LLP

20080107596 - Novel method of diagnosing, monitoring, staging, imaging and treating breast cancer: The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating breast cancer.... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.c.

20080107598 - Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications: Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are... Agent: Fulbright & Jaworski L.l.p.

20080107600 - Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same: The present invention provides a marker, kit and method for determining the level of axon outgrowth and/or fasciculation, or conditions, disorders or diseases associated with the level of axon outgrowth and/or fasciculation. The present invention was achieved by unexpectedly finding the relationship between DISC1 and FEZ1 and KIAA0844 and unexpectedly... Agent: Cozen O'connor, P.c.

20080107601 - Nanobodies tm against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neural diseases such as alzheimer's disease: The present invention relates to anti-A-beta polypeptides comprising at least one Nanobody, or a functional fragment thereof, directed against A-beta, for the treatment of diseases or disorders mediated by A-beta or dysfunction thereof, or mediated by amyloid plaque formation.... Agent: Wolf Greenfield & Sacks, P.c.

20080107603 - Neuroprotectant methods, compositions, and screening methods thereof: The present invention relates in general to methods of protecting a mammalian central nervous system cell from damage, and to methods of treating or ameliorating neurodegenerative diseases. The invention further relates to screening for neuro-protective agents that may alone, or in combination with other neuroprotective agents, aid in protecting cells... Agent: David A . Jackson Klauber & Jackson

20080107606 - Bifunctional chelators for sequestering lanthanides: The present invention relates to a method for preparing a bifunctional chelator for lanthanide. The method comprises the steps of providing a starting material which has an amino and carboxyl group; protecting the amino with an amino protecting group and the carboxyl with a carboxyl protecting group to produce a... Agent: Morrison & Foerster LLP

20080107607 - Targeting vector-phospholipid conjugates: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in... Agent: Kramer Levin Naftalis & Frankel LLP

20080107611 - Mouthwash containing fluorine and calcium ions: Mouthwash containing fluorine and calcium ions. The mouthwash has a pH value between 4.5 and 6.5 and does not contain any calcium ion sequestrants having a chelating constant with the calcium ion greater than 104. This way a mouthwash can be obtained having a high stability over time and a... Agent: Sughrue Mion, Pllc

20080107613 - Pharmaceutical composition comprising a macrolide t-cell immunomodulator and anti-photoaging agent: u

20080107616 - Composition for keratin fibres: Present invention relates to a non-aqueous aerosol composition for keratin fibres, especially for hair. It has surprisingly been found out that a water free aerosol composition comprising one or more volatile and/or non-volatile silicone oil at a concentration of at least 10% by weight, calculated to total composition, at least... Agent: Norris, Mclaughlin & Marcus, P.a.

20080107615 - Detackified compositions: The present invention relates to compositions including a detackifying effective amount of at least one polyurethane/poly(meth)acrylate graft copolymer as well as to methods of using such compositions and to kits comprising such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080107618 - Use of fullerenes for the treatment of mast cell and basophil-mediated disease: Mast cell (MC) and peripheral blood basophil (PBB)-associated diseases are treated or prevented, or their symptoms are alleviated by the administration of water soluble fullerenes (buckeyballs) to the individual under conditions sufficient to inhibit MC and PBB responses. MC and PBB responses are associated with, for example, various allergies including... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080107619 - Carbohydrate based cellulase inhibitors as feeding stimulants in termites: A method, composition and system for controlling termites wherein single carbohydrate-based compounds are used as both cellulase inhibitors and feeding stimulants. Di-saccharides, cellobioimidazole (CBI), fluoro-methyl cellobiose (FMCB), and mono-saccharides, fluoro-methyl glucose (FMG) and analogs thereof inhibit termite cellulose digestion, which leads to starvation or stimulates termite feeding to cause mortality.... Agent: Law Offices Of Brian S Steinberger

20080107620 - Human cytomegalovirus immunotherapy: An isolated protein construct comprising a polyepitope derived from multiple human cytomegalovirus protein antigen epitopes conjugated to an extracellular domain of glycoprotein B, which isolated protein is capable of eliciting a cytotoxic T-lymphocyte immune response as well as a neutralizing antibody response to human cytomegalovirus. Also provided are pharmaceutical compositions... Agent: Knobbe Martens Olson & Bear LLP

20080107622 - Galactose-pronged polysaccharides in a formulation for antifibrotic therapies: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v)... Agent: Barry Schindler C/o Greenberg Traurig, LLP

20080107621 - Use of il - 6 in microvascular complicaitions: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080107634 - Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality: The object of the present invention is a probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the contemporaneous improvement of the intestinal functionality, which can be compromised by therapeutic treatments adopted for re-solving said pathological conditions. Besides that, aim... Agent: Pearne & Gordon LLP

20080107631 - Formulation of adenovirus for gene therapy: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4°... Agent: Fulbright & Jaworski L.l.p.

20080107630 - Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus: The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic... Agent: Nixon Peabody LLP - Patent Group

20080107632 - Fibrin glue composition for repairing nerve damage and methods thereof: The present invention relates to a fibrin glue composition for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve which includes fibrin glue and an amount of bone marrow stem cells (BMSCs) effective for repairing the nerve damage and/or enhancing at least partially the functional recovery. The... Agent: Panitch Schwarze Belisario & Nadel LLP

20080107639 - Use of a dg147 protein product for preventing and treating metabolic disorders: The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding this in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080107597 - Isolation of antibodies that cross-react and neutralize rankl originating from multiple species: The invention provides specific binding members (e.g., antibodies or antigen-binding fragments thereof) which bind to RANKL originating from multiple species. An epitope recognized by the specific binding members can be selected from surface exposed loop domains that bind to and activate its cognate receptor, RANK (Receptor Activator of NFkB), on... Agent: Wilson Sonsini Goodrich & Rosati

20080107599 - Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging: Fluoroalkoxybenzamide compounds which selectively bind Sigma-2 receptors are disclosed. These compounds, when labelled with 18F, can be used as radiotracers for imaging of tumors by positron emission tomography (PET). In addition, these compounds, when labelled with 123I, can be used as radiotracers for imaging of tumors by single photon emission... Agent: Sonnenschein Nath & Rosenthal LLP

20080107602 - Neospora caninum isolate: The present invention relates to a novel Neospora caninum isolate from Nowra and extracts thereof. The strain is useful in the development of diagnostic assays for the detection of parasites in animals. The present invention also relates to pharmaceutical compositions, using live or killed organisms or extracts thereof, for the... Agent: Nixon & Vanderhye, Pc

20080107605 - Biologically active synthetic thyrotropin and cloned gene for producing same: Substantially pure recombinant TSH has been prepared from a clone comprising complete nucleotide sequence for the expression of the TSH. Diagnostic and therapeutic applications of the synthetic TSH are described.... Agent: Knobbe, Martens, Olson & Bear, LLP

20080107604 - Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests: The invention relates to a method for the prediction of the risk potential and/or diagnosis of cancerous diseases or inflammatory intestinal diseases, whereby a DNA sample is tested for the presence of polymorphic UGT1A7 allele. A positive result for a mutation is a positive indication of a sensitivity to cancerous... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080107608 - 5-substituted-2-arylpyridines: Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRP receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well... Agent: Neurogen Corporation

20080107609 - Pulmonary disease treatment: The invention relates to treating chronic obstructive pulmonary disease, involving the administration by inhalation of mometasone furoate particles in daily doses where at least about 250 μg of the inhaled particles have sizes equal to or less than 6.5 μm.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080107610 - Breath freshening and oral cleansing product with magnolia bark extract: A chewing gum composition for oral cleansing, breath freshening, and anti-microbial benefits includes Magnolia Bark extract. In a treatment process, effective amounts of Magnolia Bark extract are delivered to the oral cavity by the chewing gum composition for convenient oral cleansing and breath freshening benefits. A method of making the... Agent: Wrigley & Dreyfus 28455 Brinks Hofer Gilson & Lione

20080107612 - Anti-caries dental material: A sustained-release, dental fluoride varnish material includes about 5 percent by weight of NaF; up to about 10 percent by weight of glycerin; up to about 5 percent by weight of fumed silica; and optionally, an amount of varnish additives selected from the group consisting of flavorants, rosins, gums and... Agent: Dentsply International Inc

20080107614 - Peptide-based conditioners: Peptides have been identified that bind with high affinity to hair, skin, and nails. The peptide-based conditioners consist of a body surface-binding peptide coupled to a conditioning peptide. Conditioning peptides are typically derived from proteins and peptide having repeating amino acid sequences. Personal care compositions containing these peptide-based conditioners are... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080107617 - Surfactant-containing cosmetic, dermatological and pharmaceutical agents: The invention provides surfactant-containing cosmetic, dermatological, and pharmaceutical agents comprising at least one water-soluble or water-swellable copolymer obtainable by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, B) if desired, one or more further olefinically unsaturated, noncationic comonomers, C) if desired, one or more olefinically unsaturated, cationic comonomers, D) if desired,... Agent: Clariant Corporation Intellectual Property Department

20080107623 - Inhibitors of hepatitis c virus: e

20080107626 - Adjuvant agent for hepatitis c: An adjuvant agent is used in combination with interferon and ribavirin for treating hepatitis C. The adjuvant agent contains 50 to 90 wt % cordyceps sinensis, and also contains 10 to 50 wt % astragalus membranaceus. The cordyceps sinensis used to prepare the adjuvant agent is isolated from the culture... Agent: Birch Stewart Kolasch & Birch

20080107624 - Inhibitors of hepatitis c virus:

20080107625 - Inhibitors of hepatitis c virus:

20080107627 - Use of sarp-1 for the treatment and/or prevention of scleroderma: The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080107628 - Phosphonate inhibitors of hcv: e

20080107629 - Methods and compositions for gene therapy: The present invention relates to improved methods for gene therapy, particularly gene therapy using PEGylated adenovirus. In particular the invention provides methods and compositions for mitigating the adverse effects associated with systemic administration of recombinant adenovirus for gene therapy.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080107633 - Cultures of human cns neural stem cells: The invention provides a cell culture including proliferating human neural stem cells with a doubling rate faster than thirty days. The invention also provides a cell culture media for proliferating mammalian neural cells including a standard defined culture medium, a carbohydrate source, a buffer, a source of hormones, one or... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080107635 - Selection and use of lactic acid bacteria for reducing inflammation in mammals: Strains of lactic acid bacteria selected for their capability of reducing inflammation, such as intestinal bowel disease, a method of selecting such strains, and products containing such strains... Agent: Lynn E Barber

20080107636 - Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light: A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the... Agent: Gambro Bct, Inc Ip Department

20080107637 - Use of an agent that restores tissue perfusion and oxygenation: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080107638 - Methods of attenuating autoimmune disease and compositions useful therefor: The present invention relates to the reduction or attenuation a specific composition has on immunological tissue-destructive conditions associated with specific autoimmune diseases. The composition includes a long chain primary aliphatic alcohol, and one or more of three cofactors: a D Vitamin, a B12 Vitamin, a coenzyme Q, and an omega-3... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080107640 - Biological pesticide: Methods for exterminating pests using compositions comprising at least one protease enzyme. A detergent component may also be utilized in such compositions.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080107642 - Antibodies against gpr64 and uses thereof: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080107643 - Mammalian chemokines; receptors; reagents; uses: Novel chemokines and 7 transmembrane receptors from mammals, reagents related thereto, including purified proteins, specific antibodies, and nucleic acids encoding the chemokines and receptors are disclosed. Methods of using the chemokines, receptors, reagents and diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080107641 - Method of treating stroke with thrombolytic agent: A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus... Agent: Genentech, Inc.

20080107645 - Neospora caninum isolate: The present invention relates to a novel Neospora caninum isolate from Nowra and extracts thereof. The strain is useful in the development of diagnostic assays for the detection of parasites in animals. The present invention also relates to pharmaceutical compositions, using live or killed organisms or extracts thereof, for the... Agent: Nixon & Vanderhye, Pc

20080107644 - Pai-1 binding modulators for the treatment of ocular disorders: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 binding to vitronectin. In another embodiment, the invention concerns a method of manufacturing a compound to... Agent: Alcon

20080107646 - Method for ameliorating pruritus: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative... Agent: Occhiuti Rohlicek & Tsao, LLP

20080107647 - Methods and compositions relating to ccr5 antagonist, inf-y and il-13 induced inflammation: The present invention includes compositions and methods for the treatment of Th1 and/or Th2 medicated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5 mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and... Agent: Morgan Lewis & Bockius LLP

20080107648 - Therapeutic methods for inhibiting tumor growth with dii4 antagonists: A therapeutic method for inhibiting tumor development or growth, comprising administering an agent capable of inhibiting human delta-like ligand 4 (DII4) activity to a subject in need thereof. In one embodiment, the agent is an anti-DII4 antibody or antibody fragment capable of inhibiting the binding of DII4 to a Notch... Agent: Regeneron Pharmaceuticals, Inc

20080107651 - Humanized neutralizing antibodies against hemolytic uremic syndrome: Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080107649 - Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide: The present invention relates to biologically active compositions and methods forelliciting an immune response, particularly against amyloid beta peptides by combinatory use of virosomes as adjuvants and a synthetic beta-peptide antigen.... Agent: Kathryn Doyle Drinker Biddle & Reath LLP

20080107650 - Method for treating inflammatory diseases of the digestive tract: A method for treating an inflammatory disease of the digestive tract, for example inflammatory bowel disease, in a subject comprises administering to the subject a therapeutically effective amount of a compound selected from the group consisting of (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino]-4-methylpentanoic acid, pharmaceutically acceptable salts thereof and prodrugs thereof.... Agent: Harness, Dickey, & Pierce, P.l.c

20080107652 - Methods and compositions for control of disease in aquaculture: The invention discloses paratransgenesis methods for prevention, amelioration or treatment of a disease or disorder in an aquatic animal. The method comprises providing a genetically modified micro algae that expresses a recombinant molecule that specifically targets one or more key epitopes of a pathogen that infects the aquatic animal and... Agent: Law Offices Of Khalilian Sira, Llc

20080107654 - Humanized anti-cd47 antibody: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing... Agent: Foley And Lardner LLP Suite 500

20080107653 - Hybrid toxins comprising shiga-like toxin subunits fused to eschericihia coli heat labile enterotoxin subunits and vaccines thereof: The present invention relates to a hybrid bacterial toxin subunit, to a hybrid bipartite bacterial toxin and to nucleic acid molecules comprising a nucleotide sequence encoding such bacterial toxins. Furthermore, the invention relates to vaccines comprising said bacterial toxins and to their use in vaccines. Finally, the invention relates to... Agent: Intervet Inc. Patent Department

20080107655 - Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.... Agent: Brinks Hofer Gilson & Lione Utah Office

20080107656 - Immunogenic compositions and methods of use thereof: The present invention relates generally to a method of eliciting or otherwise inducing an immune response to a Plasmodium microorganism and compositions for use therein. More particularly, the present invention relates to a method of eliciting or otherwise inducing an immune response to a Plasmodium microorganism by administering an immunogenic... Agent: Seed Intellectual Property Law Group Pllc

20080107657 - Antibodies that bind to an epitope on the huntington's disease protein: The present invention relates generally to the generation and characterization of anti-huntingtin antibodies binding an epitope on the Huntington's disease protein. The invention further relates to the use of such anti-huntingtin antibodies in the diagnosis and treatment of Huntington's disease.... Agent: Knobbe Martens Olson & Bear LLP

20080107659 - Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after ptca: The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080107658 - Specific binding members for ngf: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080107660 - Binding agents: The invention relates to binding agents which can be induced to aggregate in response to a specific stimulus. In preferred embodiments the binding agents comprise at least a binding member for a binding partner and the binding partner. At least one of the binding member and binding partner are reversibly... Agent: Dann, Dorfman, Herrell & Skillman

20080107661 - Muc1 and abl: The present disclosure provides methods of identifying and making compounds and pharmaceutical compositions thereof that inhibit the interaction between MUC1 and Abl. The invention also provides in vivo, in vitro, and ex vivo methods of inhibiting such an interaction. Also featured are in vitro and in vivo methods of stimulating... Agent: Fish & Richardson P.c.

20080107662 - Immunogenic peptides, nucleic acids encoding the same and use thereof in cancer treatment and diagnosis: The invention discloses alternative splice variants in Philadelphia chromosome positive leukemia, immunogenic peptides and proteins thereby produced and the use thereof in the preparation of antitumor agents.... Agent: Young & Thompson

20080107663 - Tri1 cells for use in atherosclerosis: The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by... Agent: Young & Thompson

20080107665 - Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for... Agent: Bell, Boyd, & Lloyd LLP

20080107664 - Method for increasing cd8+ cytotoxic t cell responses and for treating multiple sclerosis: The present invention relates generally to the field of immunology and development of autologous vaccines. More specifically, the present invention is concerned with a method of treating autoimmune disease Multiple Sclerosis (MS) by means of immunizing patients with autologous CD8+ cells activated with fragments of Myelin Basic Protein (MBP). The... Agent: Polsinelli Shalton Flanigan Suelthaus Pc

20080107668 - Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as breast carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against breast or cancer.... Agent: Synnestvedt & Lechner, LLP

20080107669 - Method of producing an hiv-1 immune response: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or... Agent: Fitzpatrick Cella Harper & Scinto

20080107670 - Method of producing an hiv-1 immune response: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or... Agent: Fitzpatrick Cella Harper & Scinto

20080107666 - Non-glycosylated recombinant collagen-like polypeptides: The invention relates to recombinant collagen like polypeptides that are not glycosylated thereby reducing the immunogenicity of recombinant collagen-like polypeptides while at the same time preventing or reducing phosphorylation of these polypeptides. Such non-glycosylated polypeptides may be used in a wide variety of medical or cosmetic applications.... Agent: Foley And Lardner LLP Suite 500

20080107667 - Promiscuous her-2/neu cd4 t cell epitopes: The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a... Agent: Townsend And Townsend And Crew, LLP

20080107672 - Hepatitis b virus surface antigen mutant and methods of detection thereof: The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the... Agent: Paul D. Yasger Abbott Laboratories

20080107671 - Yeast-based therapeutic for chronic hepatitis c infection: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with... Agent: Sheridan Ross Pc

20080107673 - Mutants of clostridium difficile toxin b and methods of use: An active, or passive vaccine utilizing purified non-toxic mutant TcdB toxins from Clostridium difficile for humans and animals against infections caused by C. difficile and/or C. sordellii. Persons most potentially affected by C. difficile infections include hospitalized patients, infants, and elderly persons. The TcdB toxin mutant of the vaccine preferably... Agent: Dunlap Codding & Rogers, P.c.

20080107674 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group Pllc

20080107675 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group Pllc

20080107676 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group Pllc

20080107677 - Dermal drops: Dermal drops that, when applied topically to animal subjects, can ameliorate symptoms of conditions such as diabetes and Parkinson's disease are prepared as concentrates of the culture filtrate of a Basidiomycete fungus grown under appropriate conditions. The concentrate can also be used as a convenient source of liquid compost factor.... Agent: Morrison & Foerster LLP

20080107678 - Method for treating thrombotic disorders using sulfated polysaccharides: Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.... Agent: Robins & Pasternak LLP

20080107679 - Skin care compositions including hexapeptide complexes and methods of their manufacture: Skin care compositions disclosed herein include, at a minimum, safe and effective amounts of at least one wrinkle reduction agent, which is a hexapeptide, and a natural exfoliating complex. The skin care compositions provide natural skin exfoliation, reduce fine lines and wrinkles, and improve skin elasticity and firmness.... Agent: Cislo & Thomas LLP

20080107680 - Modified human growth hormone: Modified growth hormone polypeptide and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080107681 - Feline vaccines against avian influenza: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against... Agent: Judy Jarecki-black

20080107682 - Brucella melitensis mutants and methods: Certain attenuated mutants of Brucella, especially B. melitensis, B. abortus, B. suis and B. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulent Brucella of the same species does not result in disease or results in much less severe symptoms.... Agent: Greenlee Winner And Sullivan P C

20080107683 - Bacterial packaging strains useful for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof: Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080107684 - Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof: Provided is a composition comprising a phosphatidyl serine receptor ligand for use in immune therapy. The composition may include an antigen or allergen together with the phosphatidyl serine receptor ligand. The compositions may be used for any type of immune therapy, such as immune modulation to an environmental antigen or... Agent: Law Office Of Karen Canaan

20080107685 - Live attenuated dengue 3 virus strains: The invention relates to live attenuated dengue serotype 3 virus strains which have been produced by site directed mutagenesis of an attenuated dengue 3 strain.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080107686 - Vaccination with immuno-isolated cells producing an immunomodulator: The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals. These cells can be used... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.

20080107687 - Feline vaccines against avian influenza: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against... Agent: Judy Jarecki-black

20080107688 - Virulent systemic feline calicivirus: The present invention relates to a vaccine for immunization against a viral infection caused by a virulent systemic feline calicivirus (VS-FCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing... Agent: Townsend And Townsend And Crew, LLP

20080107689 - Stable microbial inoculants and methods for production of them: The invention relates to an inoculant in the form of a stable storage paste including a microorganism, a solid carrier, one or more protective substances, and water. The invention further relates to a method for producing of the inoculant using a growth medium including a solid carrier.... Agent: Cantor Colburn, LLP

20080107690 - Compositions and methods for topical application and transdermal delivery of botulinum toxins: A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and... Agent: Morgan & Finnegan, L.l.p.

20080107691 - Vibrio cholerae strains vcusm1 and vcusm4, method of producing same, and vaccine derivatives thereof: Metabolic auxotroph of Vibrio cholerae 0139 synonym Bengal which has a mutation in its hem A gene and which is not capable of synthesizing aminolevulinic acid (ALA) de novo and which is obtained from a parent strain originally isolated from a patient's coproculture having all the identifying characteristics of Vibrio... Agent: Lowe Hauptman Ham & Berner, LLP

20080107692 - Compositions and methods for the detection of trypanosoma cruzi infection: The invention provides antigenic T. cruzi polypeptides, polynucleotides, and fusions thereof, as well as compositions comprising same. Also provided are diagnostic kits and methods for the diagnosis of T. cruzi infection and in screening blood supplies.... Agent: Seed Intellectual Property Law Group Pllc

20080107693 - Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences: H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080107694 - Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier: A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.... Agent: Allergan, Inc.

20080107695 - Long-wearing cosmetic composition: The present invention relates to a cosmetic composition particularly useful for the application of color such as in a foundation, lip gloss, lip stick, mascara, eye shadow, blush, and nail polish, for example. A cosmetic composition according to the present invention includes a film-forming silicone-containing polyurethane having a viscosity from... Agent: Avon Products, Inc.

20080107697 - Cosmetic composition comprising at least one polymer particle dispersed in at least one liquid fatty phase and at least one ester of at least one acid and at least one polyol ester: The present disclosure, in one embodiment, relates to a cosmetic composition for caring for or making up the skin and/or epidermal derivatives and/or lips, which comprises a physiologically acceptable medium comprising a) at least one liquid fatty phase, b) a dispersion of at least one polymer particle dispersed in the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080107696 - Film forming composition with spreading properties: A film forming composition with spreading properties derived from an aqueous emulsion comprising (I) colloidal silica core/silicone shell particles consisting of (a) 90 wt % to 10 wt % cores of colloidal silica and (b) 10 wt % to 90 wt % shells of polyorganosiloxane; (II) a polyalkyleneoxide modified trisiloxane;... Agent: Momentive Performance Materials Inc. Ip Legal

20080107698 - Antimicrobial cellulosic sheet: A cellulosic sheet for paper towel includes an anti-microbial lotion on the towel which increases water absorbency times (WAR) to further promote lotion transfer to the skin and increase lotion transfer effectiveness.... Agent: Patent Group Ga030-43 Georgia-pacific Llc

20080107699 - Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor: A method and composition is provided for application of probiotic microorganisms to a surface to prevent contamination by pathogenic microorganisms. The probiotic microorganisms may be bacteria, yeast or mold, such as bacteria of the Lactobacillus genus. Application of probiotic microorganisms may be to surfaces such as of the hands, or... Agent: Etherton Law Group, Llc

20080107701 - Solid composition for treating water: Solid water treatment compositions are provided comprising (a) a halogen-containing source; (b) a boron-containing source; and (c) a polyphosphate-containing source. Methods for their use are also provided.... Agent: Daniel Reitenbach Chemtura Corporation

20080107700 - Use of macrolides in pest control: There is now described a method of controlling pests with macrolide compounds; more specifically A) a method of controlling pests in and on transgenic crops of useful plants, such as, for example, in crops of maize, cereals, soya beans, tomatoes, cotton, potatoes, rice and mustard, with a macrolide compound, characterized... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080107703 - Hydrogel for medical use: Disclosed is a substantially water-based medical hydrogel having at least 0.010 but no more than 50 crosslink points per molecule, as well as a dried material thereof. The hydrogel is obtained by crosslinking a gelatin having 20 to 30 amino groups per molecule and the same or greater number of... Agent: Birch Stewart Kolasch & Birch

20080107702 - Method for the immobilization of mediator molecules on inorganic and metallic implant materials: A mediator molecule is immobilized on the surface of a metallic or ceramic implant material. An anchor molecule (e.g., dialdehyde or cyanogen bromide) having a functional group that covalently binds the mediator molecule is covalently bound to the surface, and the mediator molecule is coupled to the functional group of... Agent: Foley & Lardner LLP

20080107704 - Block biodegradable copolymers for medical devices: Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes.... Agent: Medtronic Vascular, Inc. Ip Legal Department

20080107705 - Chymopapain isoenzymes, compositions, and uses thereof: The present invention provides novel chymopapain isoenzymes, compositions thereof, and methods for locally ad-ministering recombinant chymopapain or synthetic chymopapain to treat a disc disorder. Recombinant chymopapain or synthetic chymopapain useful in the methods of the invention can be naturally occurring chymopapain or variant chymopapain, including the novel chymopapain isoenzmyes of... Agent: Merchant & Gould Pc

20080107706 - Osteogenic oligonucleotides and uses thereof: Oligonucleotides having the ability to stimulate osteogenesis in vertebrate animals, including humans, are disclosed. These osteogenic oligonucleotides can be used in a wide range of clinical procedures to replace and restore osseous and periodontal defects or to facilitate the successful implantation of prosthesis and distraction procedures in bones. Methods for... Agent: Jacobson Holman Pllc

20080107707 - Polymerizable antimicrobial composition: The present invention provides a polymerizable antimicrobial composition and a method for using the same. The polymerizable antimicrobial composition of the invention comprises an antimicrobial compound, a linker, and a polymerizable function group.... Agent: Don D. Cha

20080107709 - Radio-opaque polymeric biomaterials: Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy monomers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biomaterials. Radio-opaque medical implants and drug... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080107708 - Tropoelastin-based protoelastin biomaterials: Biocompatible materials suitable for use in vascular applications have been engineered, combining human recombinant tropoelastin with other synthetic or natural biomaterials to form protoelastin. The materials can be in the form of elastin films on metal, bone, ceramic or polymer substrates, laminates of alternating polymer and elastin, blends of polymer... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080107710 - Collagen carrier of therapeutic genetic material and method: A collagen matrix material is charged with a cell growth-promoting derived nucleic acid sequence. The nucleic acid sequence-charged collagen matrix material may be utilized in a method of promoting regeneration of surface cartilage of a joint. In the method, an area of injury is covered with the nucleic acid sequence-charged... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080107711 - Bioabsorbable implantable material fortified with antibiotics for localized delivery of drugs: A bioabsorbable, implantable, flexible sheet of material contains a predetermined quantity of one or more selected antibiotics. The sheet of material is adapted to be placed inside a body for delivery of antibiotics. The sheet of material may be an implantable plastic or other suitable implantable material. The antibiotics may... Agent: Gardere Wynne Sewell LLP Intellectual Property Section

20080107712 - Ocular implant made by a double extrusion process: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.... Agent: Allergan, Inc.

20080107713 - Contact lens as a sustained drug delivery implant: A drug delivery device includes a contact lens having an optical axis and a plurality of discrete drug delivery zones asymmetrically disposed about the optical axis. A weighted area is provided in the contact lens for maintaining a presence of the contact lens upper hemispherical region in position with an... Agent: Walter A. Hackler, Ph.d. Patent Law Office

20080107714 - Use of a vector comprising a nucleic acid encoding an anti-angiogenic factor for the treatment of corneal neovascularization: The invention concerns the use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for preventing, improving and/or treating corneal neovascularization.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080107715 - Pharmaceutical containing food compositions and uses thereof: A method of delivering nutrition and one or more pharmaceutical agents to a patient after obesity surgery to enhance the patient's nutritional intake and/or compliance with oral medication(s) may include: providing a food product in an amount suitable for fitting within a stomach of the patient after the obesity surgery,... Agent: Townsend And Townsend And Crew, LLP

20080107716 - Antimicrobial tissue products with reduced skin irritation potential: A non-irritating antimicrobial multi-layer or multi-ply tissue product made by treating an inner layer or ply or an inner surface of an inner layer or ply with one or more antimicrobial agents and treating the one or more outer layers or plies or the outer surfaces of the layers or... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20080107717 - Methods and materials including treating acne related applications: The present invention provides novel methods and materials including for treating acne and including methods comprising administering to a subject a composition comprising a therapeutically effective amount of XMP.629 or a pharmaceutically acceptable salt or derivative thereof.... Agent: Bell, Boyd, & Lloyd Llc

20080107718 - Wound covering and production process: The invention relates to a production process for a foam wound dressing having an external germ barrier, more particularly a film layer, and also to a wound dressing thus obtained, having, where appropriate, a pressure-sensitive adhesive layer. In the process according to the invention the germ barrier is produced by... Agent: Shoemaker And Mattare, Ltd

20080107719 - Transdermal drug delivery system: A transdermal drug delivery system includes a drug source, an adhesive for applying the system to a skin surface, a penetration enhancer for enhancing penetration of the drug into the skin surface, an energy source and a contact for conveying energy from said energy source through said adhesive and the... Agent: Walter A. Hackler, Ph.d. Patent Law Office

20080107720 - Topical delivery of codrugs: The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same... Agent: Ropes & Gray LLP

20080107721 - Combination chemotherapy comprising a liposomal platinum complex: The present invention relates to methods for treating cancer comprising administering a combination of a liposomal platinum complex and one or more additional anticancer agents, pharmaceutical compositions comprising a liposomal platinum complex and one or more additional anticancer agents, and kits comprising unit doses of a liposomal platinum complex and... Agent: Jones Day

20080107722 - Method for loading multiple agents into delivery vehicles: This invention relates to encapsulation of drugs and other agents into preformed delivery vehicles.... Agent: Morrison & Foerster LLP

20080107724 - Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules: A method is provided for inhibiting or preventing toxicity and other unwanted effects (a) caused by solvents for pharmaceuticals which solvents or emulsifier which contain amphiphilic molecules such as polyethoxylated oils or a derivative thereof, or (b) caused by a drug in a vehicle containing amphiphilic molecules such as phopholipids... Agent: Venable LLP

20080107723 - Methods of treating pulmonary distress: Provided is a method of increasing the forced expiratory volume in one second (FEV1) in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a liposomal formulation. In some embodiments, the liposomal formulation comprises empty liposomes. Also provided is a method of increasing FEV1... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080107726 - Compositions comprising beta-adrenergic receptor antagonists and diuretics: Pharmaceutical compositions comprise beta-adrenergic receptor blocking agents for controlled release and diuretics for immediate release. In an embodiment, a composition comprising metoprolol succinate is coated onto inert particles, and the particles are further coated with a polymer to provide controlled release of metoprolol. The coated particles are coated, granulated, or... Agent: Dr. Reddy's Laboratories, Inc.

20080107725 - Pharmaceutical solid dosage forms comprising amorphous compounds micro-embedded in ionic water-insoluble polymers: The present invention provides novel pharmaceutical solid dosage forms for oral administration comprising a therapeutically effective amount of an unstable crystalline form or an amorphous form of a therapeutically effective compound micro-embedded into an ionic water-insoluble polymer. The therapeutically effective compounds, which have a tendency to gel, are micro-embedded into... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080107727 - Multiple unit oral sustained release preparation and production method thereof: Specifically, granules or powders comprising imidafenacin dispersed in a water-insoluble polymer or a higher alcohol are used in the preparation. These preparations achieve sustained release of imidafenacin since the molecular network structure that the water-insoluble polymer or the higher alcohol forms during the preparation of the granules or powders serves... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080107728 - Formula and method for making relief lozenges and method by which ingredients in lozenges are delivered to user: A lozenge or tablet which has a lozenge or tablet base, eleuthero, St. John's Wort, Valerian, and Passion flower.... Agent: Barnes & Thornburg LLP

20080107729 - Orally disintegrating compositions: This invention provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt thereof, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt... Agent: Morgan, Lewis & Bockius LLP

20080107730 - Sustained release pharmaceutical preparations and methods for producing the same: An extended release tablet comprising a core including albuterol sulfate and extended release agent; and an extended release coating on the core to provide for sustained release of the albuterol sulfate.... Agent: Foley And Lardner LLP Suite 500

20080107731 - Dpp iv inhibitor formulations: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080107732 - Gastric retention system: The present invention provides a novel gastric retention system in the form of a tablet or a capsule coated with an expandable coating, more particularly, with an expandable coating comprising a film-forming polymer and an expandable component.... Agent: Sughrue Mion, Pllc

20080107733 - Formulation obtained from a powder mixture comprising an inorganic pigment: A solid dosage form having a matrix with at least one active compound dispersed homogeneously in the matrix, which is obtainable by melting a powder mixture, wherein the powder mixture comprises at least one thermoplastic binder and a combination of highly disperse silica and at least one inorganic pigment, is... Agent: Edwards Angell Palmer & Dodge LLP

20080107734 - Healing powder and method of use thereof: A wound healing powder, comprising a sugar selected from the group consisting of one or more pharmaceutically acceptable monosaccharides and disaccharides, in an amount of at least 25% by weight of the powder mixture; and an absorbent agent which forms a bioabsorbable biocompatible matrix with wound secretions, comprising a polymer... Agent: Milde & Hoffberg, LLP

20080107735 - Macrocyclic formulations for transmembrane drug delivery: Topically applied pharmaceutical products comprising (a) an active ingredient, (b) an organogel, and (c) a non-irritating permeation enhancer, are disclosed, along with and methods of use and formulations thereof. The topically applied products and methods are intended to be used to enhance any of the transdermal, subdermal, transmembrane, musculoskeletal, transungual,... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan,

20080107743 - Composition and method for enhancing skin cell growth, proliferation and repair: A skin treatment composition is provided which contains calcium glycerophosphate and a fatty acid source derived from an animal or a vegetable. The composition enhances skin cell proliferation and growth and repair of damage to skin cells. Methods for enhancing skin cell repair, proliferation, and growth and for enhancing ceramide... Agent: Panitch Schwarze Belisario & Nadel LLP

20080107737 - Crosslinked amine polymers: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment... Agent: Senniger Powers LLP (ilps)

20080107744 - Injectable hollow tissue filler: The present invention comprises a plurality of injectable hollow particulate fillers suspended in a biocompatible fluid carrier to significantly improve the clumping resistance and injectability of the composition. The hollow particulate fillers have a lower effective density and are able to suspend in the carrier without precipitation. The loss of... Agent: Jack Chu

20080107739 - Medical nanobody: A particle-sized nanobody that can be inserted into at least one major physiological system of a mammal's body such as the blood stream or the gastro-intestinal track or other system. The nanobody of the present invention can remain in the system for a predetermined time to perform a predetermined task.... Agent: Clifford Kraft

20080107738 - Ophthalmic emulsions containing prostaglandins: Cationic ophthalmic oil-in-water type emulsions, include colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent and at least one non ionic surfactant, the oily core including a prostaglandin selected from the group comprising in particular latanoprost, unoprostone isopropyl, travoprost, bimatoprost,... Agent: Young & Thompson

20080107736 - Pharmaceutically active nanosuspensions: The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants... Agent: Grossman, Tucker, Perreault & Pfleger, Pllc

20080107746 - Anti-inflamatory inhalation pharmaceutical composition: The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. This observed inflammation reduction in the lungs and/or the nasal cavity is confirmed by the diminution of at least one of the following... Agent: Lowe Hauptman Ham & Berner, LLP

20080107742 - Compositions and methods for removing urushiol and treating the resulting skin condition: The present application is directed to various compositions to treat the itching and conditions that result from contracting poison ivy, poison oak, and poison sumac, as well as other plant and substances that contain substances that lead to a skin reaction but that upon removal alleviate the symptoms of the... Agent: William Douglas Hare

20080107745 - Controlled release sterile injectable aripiprazole formulation and method: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Agent: Sughrue Mion, Pllc

20080107741 - Nanoparticulate compositions of angiogenesis inhibitors: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.... Agent: Foley & Lardner LLP

20080107740 - Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders: Pharmaceutical composition for inhalation, containing as active ingredient effective amounts of salmeterol or a physiologically salt of salmeterol or a solvate thereof, and budesonide or a therapeutically salt of budesonide or a solvate thereof, wherein the molecular ratio of salmeterol component to budesonide component is in the range 1:2 to... Agent: Dickinson Wright Pllc

20080107747 - Pain relief composition: Disclosed is a pain relief composition comprising an effective amount of a nerve inhibiting component, including capsaicin, a capsaicinoid or a capsaicin analogue, which numbs or inhibits the nerve endings that signal pain, in combination with at least one of the following: an effective amount of an inflammation control component... Agent: Cislo & Thomas LLP

20080107748 - Microcapsules for removing and absorbing a chemical from a mixture: A microcapsule comprising a chemical skeleton with at least one ligand attached to the chemical skeleton. The chemical skeleton is placed within a capsule. The capsule can then separate a substance from a mixture. The capsule is placed within the mixture and the substance is allowed to enter the capsule.... Agent: Nathaniel Gordon-clark

20080107749 - Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles: Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropyl acrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpyrolidone (VP) or vinyl acetate (VA),... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080107750 - Graft materials containing ecm components, and methods for their manufacture: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080107751 - Antimicrobial wax composition for wax therapy: A wax composition comprises a wax and an antimicrobial agent in an amount effective to inhibit the growth of micro-organisms in the wax in both solid and liquid states. According to the preferred embodiment of the present invention, the wax composition comprises a wax that is solid at room temperature,... Agent: Storm LLP

20080107752 - Modified elapid venoms as stimulators of the immune reaction: Detoxified cobra venom and its constituent neurotoxins have been reported to have potent antiviral activity. Others have reported that snake venoms were generally immune stimulants. Recent research has revealed more specific details on the effects of detoxified venoms and isolated alpha-neurotoxins on cells of the immune system. Exposure of the... Agent: Robert J. Van Der Wall Gables One Tower

20080107753 - Compositions to alleviate menopausal symptoms: Compositions and methods of preparing and using such compositions to treat the symptoms of perimenopause and menopause.... Agent: Cr Miles, P.c. Craig R. Miles

20080107754 - Dietary supplement and a method to enhance sleep and lucid dreaming: A nutritional supplement for enhancing sleep and lucid dreaming in humans. It contains a combination of ingredients in proportions calculated to enhance lucid dreaming. The primary ingredients are Calea zacatechichi, L-5-Hydroxytryptophan (L-5-HTP), and Vinpocetine. In addition, the nutritional supplement may include the secondary ingredient Melatonin and the tertiary ingredients Wild... Agent: Brown & Michaels, Pc 400 M & T Bank Building

20080107755 - Methods and compositions for altering cell function: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX), when administered... Agent: Casimir Jones, S.c.

20080107756 - Lithium combinations, and uses related thereto: The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor... Agent: Irving M. Fishman C/o Cohen, Tauber, Spievack, And Wagner

20080107757 - Sophorae subprostratae radix extract for prevention and treatment of respiratory diseases: The present invention relates to an extract isolated from Sophorae Radix useful for prevention and treatment of respiratory diseases. More specifically, the present invention relates to a pharmaceutical drug comprising the Sophorae Radix extract having excellent effects of inhibiting airway contraction, respiratory infections, 5-lipoxygenase activity, phosphodiesterase 4 activity, airway hyper-responsiveness... Agent: Frommer Lawrence & Haug

20080107758 - Topical steroid spray with botanic seed oils: A pharmaceutical topical spray composition of corticosteroid, an alcohol, a propellant, and botanic seed oils having a blend of black raspberry seed oil, black cumin seed oil, and red raspberry seed oil prepared according to a cold press method. A method for treating an inflammatory skin condition using the administration... Agent: Briggs And Morgan P.a.

20080107760 - Beverage and medicament containing bamboo extract as a main ingredient: The present invention relates to a beverage containing bamboo extract as a main ingredient, for details, a beverage containing bamboo extract as the main ingredient, which is useful for amelioration of diabetes, cancer, life-style related diseases or the like. A beverage characterized in containing, as the main ingredient, bamboo extract... Agent: Ladas & Parry

20080107759 - Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease: The present invention relates to a composition comprising a bamboo plant extract for the prevention and treatment of inflammatory or blood circulation disease. The extracts of bamboo plant has potent anti-inflammatory activity by inhibiting NO production and blood circulation-improving activity by inhibiting elastase activity and healing the wound of vascular... Agent: Swanson & Bratschun, L.l.c.

20080107761 - Composition and method for promoting the production of and/or enhancing the activity of fibulin-5: There is provided a composition for promoting the production of and/or enhancing the activity of fibulin-5, said composition comprising as an active ingredient one or a plurality of pharmaceutical agents selected from the group consisting of extracts of Caesalpinia crista, extracts of Psophocarpus tetragonolobus, phytic acid and a pharmaceutically acceptable... Agent: Snider & Associates

20080107762 - Neurotoxin component treatment for spasticity: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20080107763 - Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20080102026 - Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy... Agent: Clark & Elbing LLP

20080102027 - Targer for b-cell disorders: The present invention relates to the diagnosis and treatment of B-cell disorders such as multiple myeloma (MM). In particular, the present invention relates to the treatment of B-cell disorders using ligands which bind to free lambda light chains expressed on the surface of lymphoid cancer cells.... Agent: Marshall, Gerstein & Borun LLP

20080102028 - Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(i) tetrafluoroborate: The present invention relates to new synthetic methods for preparing 2-methoxyisobutylisonitrile and metal isonitrile complexes, such as tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluroroborate, which are used in the preparation of technetium (99mTc) Sestamibi, and novel intermediate compounds useful in such methods.... Agent: Darby & Darby P.C.

20080102033 - Preparation for the prophylaxis of restenosis: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one... Agent: Millen, White, Zelano & Branigan, P.C.

20080102034 - Preparation for the prophylaxis of restenosis: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one... Agent: Millen, White, Zelano & Branigan, P.C.

20080102035 - Medical device having discrete regions: An apparatus prepares a medical device from a polymeric composition having properties such as increased visibility of the device and the ability to deliver therapeutic and other agents. The device is constructed with additives incorporated into the polymeric structure, such as a material that increases visibility of the device, while... Agent: Philip S. Johnson Johnson & Johnson

20080102036 - Biocompatible fluorescent silicon nanoparticles: The invention features biocompatible fluorescent nanoparticle and their use in in vivo imaging methods.... Agent: Goodwin Proctor

20080102039 - Betamethasone spray: A spray foaming dosage form comprising betamethasone valerate, dimethyl isosorbide, propylene glycol, non ionic surfactant, sodium dodecyl sulphate, a buffer, optional preservative, optional further excipients, and water.... Agent: Daniel B. Schein, Ph.d., Esq., Inc.

20080102038 - Clobetasol spray: A spray foaming dosage form comprising clobetasol propionate, dimethyl isosorbide, propylene glycol, polysorbate, sodium dodecyl sulphate, buffer, optional preservative, optional further excipients, and water.... Agent: Daniel B. Schein, Ph.d., Esq., Inc.

20080102042 - Oral composition: The present invention provides an oral composition which is effective for the prevention or treatment of periodontal disease such as gingivitis, periodontitis and alveolar pyorrhea. According to the present invention, there can be provided an oral composition such as a dentifrice, a mouthwash or a gingival massage cream which is... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080102041 - Teeth stain inhibitor composition and methods of use thereof: The invention provides ingestible compositions for reducing or inhibiting teeth stain, and methods for using the same.... Agent: Faegre & Benson LLP Patent Docketing

20080102044 - Raw material for cosmetic preparation containing benzoate and cosmetic preparation containing such raw material: Disclosed is a raw material for cosmetic preparations having excellent gloss imparting properties and oxidation stability. Also disclosed is a cosmetic preparation having excellent gloss and feeling of use. The raw material for cosmetic preparations contains an ester compound of (A) benzoic acid, (B) an alcohol selected from the group... Agent: Mcginn Intellectual Property Law Group, PLLC

20080102048 - Long-wearing cosmetic product system for providing extended shine and gloss: A method of making-up a keratinous substrate involving: (a) providing a keratinous substrate; (b) applying a basecoat composition onto the keratinous substrate, the basecoat composition comprising: (i) at least one silicone- polyamide copolymer; (ii) at least one silicone film former; (iii) at least one volatile oil; and (iv) at least... Agent: L'oreal Usa/ Patent Department

20080102049 - Long-wearing cosmetic product system having high shine and gloss: A method of making-up a keratinous substrate involving: (a) providing a keratinous substrate; (b) applying a basecoat composition onto the keratinous substrate, the basecoat composition comprising: (i) at least one (co)polymer comprising at least one organosiloxane unit and at least two other groups capable of forming hydrogen interactions chosen from... Agent: L'oreal Usa/ Patent Department

20080102050 - Water-based skin care composition with polyalkylsilsesquioxane powder emulsion and method for making the same: A process for making a water-based skin care composition including blending a polyalkylsilsesquioxane powder emulsion and water. A skin care composition made by the process is also presented, which is easy to prepare and do not require additional heating or further emulsification of the skin care formulation.... Agent: General Electric Co. Global Patent Operation

20080102051 - Use of polyols to increase stiffness in lo